Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Ventolin HFA Switch From CFC Inhaler Has Comparable Asthma Efficacy

Executive Summary

GlaxoSmithKline Ventolin HFA labeling states that switching to the non-chlorofluorocarbon inhaler from a CFC-propelled product does not result in "any clinically significant changes in the efficacy profile."

You may also be interested in...



GSK Ventolin HFA roll-out

Ventolin CFC version of inhalation asthma agent will be phased out in next 10 to 15 months following Feb. 20 launch of albuterol HFA, GlaxoSmithKline said. Ventolin HFA's wholesale acquisition cost will be same as its successor: $29.99 for 100 mcg. Ventolin HFA was approved in April 2001 (1"The Pink Sheet" April 23, 2001, p. 34)...

GSK Ventolin HFA roll-out

Ventolin CFC version of inhalation asthma agent will be phased out in next 10 to 15 months following Feb. 20 launch of albuterol HFA, GlaxoSmithKline said. Ventolin HFA's wholesale acquisition cost will be same as its successor: $29.99 for 100 mcg. Ventolin HFA was approved in April 2001 (1"The Pink Sheet" April 23, 2001, p. 34)...

Glaxo Ventolin HFA phase-in

Non-chlorofluorocarbon albuterol inhaler Ventolin HFA will gradually replace existing CFC product following launch, GlaxoSmithKline says. Company is meeting with physicians and patients to determine the best way to implement the CFC phase-out. Ventolin HFA was approved April 12 (1"The Pink Sheet" April 23, p. 34)

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel